Eric Ostertag - Aug 6, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol: PSTX
Transactions as of: Aug 6, 2021
Transactions value $: $1,017,013
Form type: 4
Date filed: 8/10/2021, 06:56 PM
Previous filing: Aug 4, 2021
Next filing: Sep 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Options Exercise	$1.02M	+111K	+20.47%	$9.15	654K	Aug 6, 2021	Direct
holding	PSTX	Common Stock						3.74M	Aug 6, 2021	See footnote	F1
holding	PSTX	Common Stock						3.43M	Aug 6, 2021	See footnote	F2
holding	PSTX	Common Stock						629K	Aug 6, 2021	See footnote	F3
holding	PSTX	Common Stock						961K	Aug 6, 2021	See footnote	F4
holding	PSTX	Common Stock						201K	Aug 6, 2021	See footnote	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Options Exercise	$0	-111K	-12.5%	$0.00	778K	Aug 6, 2021	Common Stock	111K	$9.15	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F2	The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3	The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F4	The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
F5	The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
F6	12.5% of the shares subject to the stock option vested and became exercisable on the August 4, 2021, and the remaining shares will vest in 42 equal monthly installments thereafter.